Local diagnostics company One BioMed Pte Ltd and A*STARs Genome Institute of Singapore (GIS) have established a joint laboratory to develop molecular diagnostic assays for the Asian clinical infectious disease testing market. <\/p>\n
The joint laboratory will focus on the full development and integration of the initial assays for the One BioMed platform. Each panel will be multiplexed and syndromic, and is expected to address clinically important infectious diseases in Asia, including pediatric respiratory infections, drug resistant tuberculosis and mosquito-borne illnesses. The laboratory will be located in the Genome building at Biopolis and will leverage the genomic expertise of GIS to improve the delivery of clinical medicine. <\/p>\n
One BioMed recently spun-out of A*STARs Institute of Microelectronics (IME) is developing a point-of-care diagnostic platform deploying two proprietary technologies: a chemistry-based nucleic acid extraction and a silicon biophotonics dual-ring sensor. Integrated into a consumable cartridge design and run on a portable instrument, these approaches are expected to enable simple, cost-effective, rapid and highly multiplexed molecular testing outside of a central laboratory setting. <\/p>\n
Dr Alexander Lezhava, Group Leader, Translational Research will lead the lab for GIS, and Dr Park Mi Kyoung, founder and Chief Technology Officer of One BioMed, will lead the lab for the company. We allied with the GIS Translational Research group because they combine extensive molecular diagnostics assay development expertise with regulatory and commercialisation experience, said Dr Park. <\/p>\n
Prof Ng Huck Hui, Executive Director of GIS said, Our collaboration with One BioMed helps us address one of the most difficult problems facing patients and healthcare providers across the region poor access to accurate testing for infectious diseases like influenza, dengue and tuberculosis. <\/p>\n
<\/p>\n
Read this article: Local diagnostics company One BioMed Pte Ltd and A*STARs Genome Institute of Singapore (GIS) have established a joint laboratory to develop molecular diagnostic assays for the Asian clinical infectious disease testing market. The joint laboratory will focus on the full development and integration of the initial assays for the One BioMed platform. Continue reading
\nOne BioMed and A*STAR's Genome Institute of Singapore establish joint lab - Enterprise Innovation<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"